Literature DB >> 12633499

Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.

Susanne Leder1, Hanna Czajkowska, Barbara Maenz, Katrin De Graaf, Andreas Barthel, Hans-Georg Joost, Walter Becker.   

Abstract

The dual specificity tyrosine phosphorylated and regulated kinase (DYRK) family of protein kinases is a group of evolutionarily conserved protein kinases that have been characterized as regulators of growth and development in mammals, Drosophila and lower eukaryotes. In the present study, we have characterized three splicing variants of DYRK1B (DYRK1B-p65, DYRK1B-p69 and DYRK1B-p75) with different expression patterns and enzymic activities. DYRK1B-p65 and DYRK1B-p69 exhibited similar, but not identical, patterns of expression in mouse tissues, with the highest protein levels found in the spleen, lung, brain, bladder, stomach and testis. In contrast, DYRK1B-p75 was detected specifically in skeletal muscles, in the neuronal cell line GT1-7 and also in differentiated, adipocyte-like 3T3-L1 cells, but not in undifferentiated 3T3-L1 preadipocytes. A comparison of the mouse and human Dyrk1b genomic and cDNA sequences defined the alternative splicing events that produce the variants of DYRK1B. In DYRK1B-p75, transcription starts with exon 1B instead of exon 1A, generating a new translation start, which extends the open reading frame by 60 codons. This gene structure suggests that alternative promoters direct the expression of DYRK1B-p69 and DYRK1B-p75. Both splicing variants exhibited kinase activity in vitro and contained phosphotyrosine when expressed in COS-7 cells. Owing to differential recognition of the 3'-splice site in exon 9, DYRK1B-p65 differs from DYRK1B-p69 by the absence of 40 amino acids within the catalytic domain. DYRK1B-p65 lacked kinase activity in vitro and did not contain phosphotyrosine. DYRK1B-p69 and DYRK1B-p75 stimulated reporter gene activity driven by the f or kh ead in r habdosarcoma (FKHR)-dependent glucose-6-phosphatase promoter more strongly when compared with DYRK1B-p65, indicating that the DYRK1B splicing variants exhibit functional differences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633499      PMCID: PMC1223441          DOI: 10.1042/BJ20030182

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival.

Authors:  Ke Li; Shuqing Zhao; Vinit Karur; Don M Wojchowski
Journal:  J Biol Chem       Date:  2002-09-27       Impact factor: 5.157

2.  Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo.

Authors:  A B Lassar; R L Davis; W E Wright; T Kadesch; C Murre; A Voronova; D Baltimore; H Weintraub
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

3.  The signaling potential of the receptors for insulin and insulin-like growth factor I (IGF-I) in 3T3-L1 adipocytes: comparison of glucose transport activity, induction of oncogene c-fos, glucose transporter mRNA, and DNA-synthesis.

Authors:  M Weiland; F Bahr; M Höhne; A Schürmann; D Ziehm; H G Joost
Journal:  J Cell Physiol       Date:  1991-12       Impact factor: 6.384

4.  A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region.

Authors:  J Guimerá; C Casas; C Pucharcòs; A Solans; A Domènech; A M Planas; J Ashley; M Lovett; X Estivill; M A Pritchard
Journal:  Hum Mol Genet       Date:  1996-09       Impact factor: 6.150

5.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

Review 6.  A template for the protein kinase family.

Authors:  S S Taylor; D R Knighton; J Zheng; J M Sowadski; C S Gibbs; M J Zoller
Journal:  Trends Biochem Sci       Date:  1993-03       Impact factor: 13.807

7.  Metabolism of pro-luteinizing hormone-releasing hormone in immortalized hypothalamic neurons.

Authors:  W C Wetsel; P L Mellon; R I Weiner; A Negro-Vilar
Journal:  Endocrinology       Date:  1991-09       Impact factor: 4.736

8.  minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila.

Authors:  F Tejedor; X R Zhu; E Kaltenbach; A Ackermann; A Baumann; I Canal; M Heisenberg; K F Fischbach; O Pongs
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

9.  Cloning and sequencing of the 5' region of the human glucose-6-phosphatase gene: transcriptional regulation by cAMP, insulin and glucocorticoids in H4IIE hepatoma cells.

Authors:  D Schmoll; B B Allan; A Burchell
Journal:  FEBS Lett       Date:  1996-03-25       Impact factor: 4.124

10.  DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression.

Authors:  Florian von Groote-Bidlingmaier; Dieter Schmoll; Hans Martin Orth; Hans Georg Joost; Walter Becker; Andreas Barthel
Journal:  Biochem Biophys Res Commun       Date:  2003-01-17       Impact factor: 3.575

View more
  25 in total

Review 1.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

2.  The phosphorylation status of T522 modulates tissue-specific functions of SIRT1 in energy metabolism in mice.

Authors:  Jing Lu; Qing Xu; Ming Ji; Xiumei Guo; Xiaojiang Xu; David C Fargo; Xiaoling Li
Journal:  EMBO Rep       Date:  2017-03-31       Impact factor: 8.807

3.  Splice variants of the dual specificity tyrosine phosphorylation-regulated kinase 4 (DYRK4) differ in their subcellular localization and catalytic activity.

Authors:  Chrisovalantis Papadopoulos; Krisztina Arato; Eva Lilienthal; Johannes Zerweck; Mike Schutkowski; Nicolas Chatain; Gerhard Müller-Newen; Walter Becker; Susana de la Luna
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

4.  Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.

Authors:  Yasushi Ogawa; Yosuke Nonaka; Toshiyasu Goto; Eriko Ohnishi; Toshiyuki Hiramatsu; Isao Kii; Miyo Yoshida; Teikichi Ikura; Hiroshi Onogi; Hiroshi Shibuya; Takamitsu Hosoya; Nobutoshi Ito; Masatoshi Hagiwara
Journal:  Nat Commun       Date:  2010-10-05       Impact factor: 14.919

5.  Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.

Authors:  Jing Hu; Eileen Friedman
Journal:  Genes Cancer       Date:  2010-08-01

6.  Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.

Authors:  Daina Z Ewton; Jing Hu; Maria Vilenchik; Xiaobing Deng; Kin-Chun Luk; Ann Polonskaia; Ann F Hoffman; Karen Zipf; John F Boylan; Eileen A Friedman
Journal:  Mol Cancer Ther       Date:  2011-08-30       Impact factor: 6.261

7.  The zebrafish dyrk1b gene is important for endoderm formation.

Authors:  Gohar Mazmanian; Michael Kovshilovsky; Debbie Yen; Aditya Mohanty; Sudipta Mohanty; Alex Nee; Robert M Nissen
Journal:  Genesis       Date:  2010-01       Impact factor: 2.487

8.  Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes.

Authors:  Eva Lilienthal; Katharina Kolanowski; Walter Becker
Journal:  BMC Biochem       Date:  2010-05-20       Impact factor: 4.059

9.  Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.

Authors:  Xiaobing Deng; Daina Z Ewton; Eileen Friedman
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  The kinase Mirk is a potential therapeutic target in osteosarcoma.

Authors:  Cao Yang; Diana Ji; Edward J Weinstein; Edwin Choy; Francis J Hornicek; Kirkham B Wood; Xianzhe Liu; Henry Mankin; Zhenfeng Duan
Journal:  Carcinogenesis       Date:  2009-12-30       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.